pulmonologyadvisor22h
Shifting Perspectives: Providing Weight-Inclusive Health Care in the GLP-1 Era
Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...
Ulster University2mon
Targeting glucagon-like peptides for the treatment of diabetes and obesity
Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...
Nature4y
G-Protein-Coupled Receptors, Pancreatic Islets, and Diabetes
such as glucagon-like peptide-1, free fatty acids, and catecholamines. With this knowledge, scientists are seeking to better understand the role of GPCRs in islet biology and hormone secretion ...
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29
Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...
Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
EurekAlert!24d
Factors associated with semaglutide initiation among adults with obesity
a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in those without diabetes. These findings suggest that insurance plan type and structure may be a crucial intervention point ...